Cosmos Health projects over $22.7M revenue from four US products

Cosmos Health Inc. (NASDAQ: COSM) announced projected annualized revenue exceeding $22.7 million and gross profit of approximately $17.0 million from four products in its 18 Series nutraceutical line launched in the United States.

The company has introduced five products in the 18 Series platform: Noor18, Liv18, Cur18, Fort18, and Oliv18. Four products have disclosed revenue projections, with Noor18 targeting over $12.0 million in annualized US revenue, Liv18 over $5.0 million, Fort18 over $3.2 million, and Cur18 over $2.5 million.

The company expects gross margins of approximately 75% across these products. Noor18 focuses on healthy aging and beauty, Liv18 on liver and metabolic support, Fort18 on men's wellness, and Cur18 on inflammation and mobility.

Cosmos Health plans to develop a portfolio of 18 science-based products spanning health categories. The products are currently sold direct-to-consumer, with plans to expand into additional retail channels. All products are manufactured in the US at GMP-certified, FDA-registered facilities.

"Our US entry is active, generating revenue, and showing encouraging early momentum," said CEO Greg Siokas in a statement. The company expects the 18 Series to become a significant contributor to long-term revenue and profitability.

Cosmos Health operates as a diversified healthcare group with pharmaceutical and nutraceutical brands. The company manufactures products through its European subsidiary and distributes pharmaceuticals in Greece and the UK. It has also entered telehealth through its acquisition of ZipDoctor Inc.

You May Also Be Interested In

• Cantor Fitzgerald Starts Tempus AI Inc (TEM) at Overweight
• Booz Allen says AI can now execute cyberattacks without human input
• AIG board names John Rice as chair, Zaffino moves to advisor